Relationships among microbiota, gastric cancer, and immunotherapy

Yuzhen Li; Xiaona Huang; Desheng Tong; Chenyu Jiang; Xiaodan Zhu; Zhipeng Wei; Tingjie Gong; Chunhui Jin

doi:10.3389/fmicb.2022.987763

Relationships among microbiota, gastric cancer, and immunotherapy

Front Microbiol. 2022 Sep 12:13:987763. doi: 10.3389/fmicb.2022.987763. eCollection 2022.

Authors

Yuzhen Li¹, Xiaona Huang¹, Desheng Tong², Chenyu Jiang¹, Xiaodan Zhu¹, Zhipeng Wei¹, Tingjie Gong¹, Chunhui Jin¹

Affiliations

¹ Department of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, China.
² Key Laboratory of National Health and Family Planning Commission on Parasitic Disease Control and Prevention, Jiangsu Provincial Key Laboratory on Parasite and Vector Control Technology, Jiangsu Institute of Parasitic Diseases, Wuxi, China.

Abstract

Currently, conventional neoadjuvant therapy or postoperative adjuvant therapy, such as chemotherapy and radiation therapy, can only bring limited survival benefits to gastric cancer (GC). Median survival after palliative chemotherapy is also low, at about 8-10 months. Immunotargeting is a new option for the treatment of GC, but has not been widely replicated. The highly immunosuppressed tumor microenvironment (TME) discounts the efficacy of immunotherapy for GC. Therefore, new strategies are needed to enhance the immune response of the TME. This paper reviewed the relationship between microorganisms and GC, potential links between microorganisms and immunotherapy and research of microorganisms combined immunotherapy.

Keywords: CTLA-4; PD-L1; gastric cancer; immune checkpoint inhibitors; immune response; microbiota.

Publication types

Review